Research Article

Delayed Graft Function in Kidney Transplants: Time Evolution, Role of Acute Rejection, Risk Factors, and Impact on Patient and Graft Outcome

Martin Chaumont, 1 Judith Racapé, 2 Nilufer Broeders, 1 Fadoua El Mountahi, 1 Annick Massart, 1 Thomas Baudoux, 1 Jean-Michel Hougardy, 1 Dimitri Mikhalsky, 1 Anwar Hamade, 1 Alain Le Moine, 1 Daniel Abramowicz, 3 and Pierre Vereerstraeten 1

1 Department of Nephrology, Dialysis and Transplantation and Department of Abdominal Surgery, CUB, Erasmus Hospital, Route de Lennik 808, 1070 Brussels, Belgium
2 Research Center of Biostatistics, Epidemiology and Clinical Research, School of Public Health, Route de Lennik 808, 1070 Brussels, Belgium
3 Nephrology Department, Antwerp University Hospital, Free University of Brussels, Wilrijkstraat 10, 2650 Edegem, Belgium

Correspondence should be addressed to Martin Chaumont; martin.chaumont2012@gmail.com

Received 29 April 2015; Accepted 26 August 2015

Academic Editor: F. H. J. Claas

Copyright © 2015 Martin Chaumont et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although numerous risk factors for delayed graft function (DGF) have been identified, the role of ischemia-reperfusion injury and acute rejection episodes (ARE) occurring during the DGF period is ill-defined and DGF impact on patient and graft outcome remains controversial. Methods. From 1983 to 2014, 1784 kidney-only transplantations from deceased donors were studied. Classical risk factors for DGF along with two novel ones, recipient’s perioperative saline loading and residual diuresis, were analyzed by logistic regression and receiver operating characteristic (ROC) curves. Results. Along with other risk factors, absence of perioperative saline loading increases acute rejection incidence (OR = 1.9 [1.2–2.9]). Moreover, we observed two novel risk factors for DGF: patient’s residual diuresis ≤ 500 mL/d (OR = 2.3 [1.6–3.5]) and absence of perioperative saline loading (OR = 3.3 [2.0–5.4]). Area under the curve of the ROC curve (0.77 [0.74–0.81]) shows an excellent discriminant power of our model, irrespective of rejection. DGF does not influence patient survival (P = 0.54). However, graft survival is decreased only when rejection was associated with DGF (P < 0.001). Conclusions. Perioperative saline loading efficiently prevents ischemia-reperfusion injury, which is the predominant factor inducing DGF. DGF per se has no influence on patient and graft outcome. Its incidence is currently close to 5% in our centre.

1. Introduction

Delayed graft function (DGF) is a common complication most frequently defined as the need for dialysis during the first posttransplant week [1]. DGF results from immunologic and nonimmunologic events that start during kidney preservation and progress after the time of reperfusion [2]. DGF incidence depends on its definition [1], on the risk profiles of the donor and the recipient [3], and on the transplant centre [4]. Over the past decade, there have been important advances in the field of transplantation particularly with regard to immunosuppression [5] and organ allocation strategies [6] leading to reduced DGF incidence but it is expected to rise in the future due to the increasing use of kidneys from extended criteria and donation after cardiac death (DCD) donors who show more DGF versus standard criteria donors [7]. In the last thirty years, several studies report DGF incidences in adult recipients from deceased kidney donor transplants to be within the 15–30% range [3].

In 2003, Irish et al. developed the first multivariable logistic regression model to quantify the risk of DGF using donor and recipient characteristics at the time of transplantation [3] and in 2010 they refined their model and found that the main risk factors for DGF are cold ischemia time, donor’s...
terminal serum creatinine, recipient body mass index (BMI), DCD donor, and donor’s age ≥16 years [8]. In recent years, although much effort has been made to identify the risk factors for DGF, its cause was scarcely investigated. Ischemia-reperfusion injury and acute rejection episodes occurring during the DGF period are both the main causal mechanisms of DGF and they are hard to distinguish from each other as they are highly correlated [9]. Furthermore, the impact of DGF on patient and graft outcome is controversial due to lack of control for acute rejection in most analyses. Some studies found shorter allograft survival regardless of rejection occurrence [10–12] but others did not [13, 14]. Altogether, DGF seems to decrease long-term graft survival as a result of combined ischemia-reperfusion injury and early rejection [15].

Given the burden of DGF impact, many strategies are now at different stages of development, which might reduce the risk of DGF in the future, but there are no approved strategies for DGF prevention to date [7]. Of course, some factors could be modified: cold ischemia time should be kept as low as possible [14] and immunosuppressive therapy adapted to the patient with high DGF risk [14, 16], but these modifications are not always feasible. Readily accessible methods to minimize ischemia-reperfusion injury include, for example, maintenance of an adequate patient’s perioperative intravascular volume [17]. Surprisingly, predictive models of DGF do not take the recipient’s perioperative hemodynamics into account [3, 8, 18, 19].

In our centre, DGF incidence dropped steeply in 1992 and subsequently decreased continuously until reaching a record low since 2010, close to 5%. Our aim was to answer four questions: (1) What are the factors behind the decrease in DGF incidence in our cohort across the three past decades? (2) What role does rejection play in DGF occurrence? (3) What are the risk factors for DGF taking rejection into account or not? (4) Does DGF impact patient and graft outcome differently with and without rejection?

2. Patients and Methods

From August 25, 1983, when cyclosporin was first used at our centre, to June 30, 2014, which defines the end of the study period, 1784 consecutive kidney-only transplantations from deceased donors have been carried out on 1452 adult (≥15 years old) recipients. The immunosuppressive protocol on an intent-to-treat basis included, along with corticosteroids, a calcineurin inhibitor either cyclosporin (n = 1046) or tacrolimus (n = 690) and an antiproliferative medication either azathioprine (n = 191) or mycophenolate mofetil (n = 684) and it was associated in most cases with an antilymphocyte induction therapy consisting in either a polyclonal globulin (antithymocyte, n = 285) or a monoclonal globulin directed to the CD3 receptor (OKT3, n = 578) or to the IL-2 receptor (basiliximab or daclizumab, n = 605). A few patients received sirolimus (n = 48) and others an anti-LFA1 induction therapy (n = 13). Few transplantations (n = 32) were preemptive.

Since 1992, a protocol of perioperative saline loading of the recipient has been implemented in our center to prevent hypovolemia [20]. First, during a period of 3 to 4 hours prior to transplantation, the patient receives infusion of 0.9% NaCl; the volume is adapted to the state of hydration and, in case of euvolemia, maintained at a 30 mL/h rate. Second, 0.9% NaCl is infused in the operating room at a maximal 600 mL/h rate until target central venous pressure between 4 and 8 mmHg is obtained and then reduced to 30 mL/h to maintain this pressure. During the first eight hours after transplantation, if recipient’s diuresis is more than 20 mL/h, it is compensated by 0.45% NaCl-5% glucose infusion at a maximal 200 mL/h rate, and if diuresis is lower than 20 mL/h, furosemide (250 mg IV) is given and the infusion reduced to a 30 mL/h rate. After the first eight hours, 500 or 1000 mL of the same infusion is given every 12 hours if diuresis is less or more than 20 mL/h, respectively. All preservation infusions used for the cold storage were of the intracellular type and penicillin, insulin, and hydrocortisone were at times added.

Rejection episodes occurring during the DGF period were recorded. The diagnosis was established, first from clinical data (decrease in diuresis, swelling and tenderness of the graft, and malaise) and then from the rise in serum creatinine [21], and finally confirmed by kidney biopsy which has been almost systematic since the early nineties and characterized according to the Banff classification since 1998. These rejection episodes (including Banff borderline ARE) were all treated with transitorily increased corticosteroid doses or, in a few cases of corticoresistance, with thymoglobulin and/or plasmapheresis or, more recently, with intravenous immunoglobulin administration when CD4 positive cells expressing humoral rejection were identified.

DGF was defined as the need for dialysis in the postoperative course irrespective of its duration. Grafts that never functioned due to technical failures, arterial and/or venous thrombosis (n = 33), primary nonfunction (n = 9), or urological problems (n = 8), were not considered as DGF, as regular dialysis was not interrupted.

Most recipient, donor, and transplant characteristics reported in the literature as risk factors for DGF were considered [3]. Some of them were rather infrequent in our centre and were therefore not taken into account, such as recipient’s ethnicity (3% black Africans), machine-perfusion preservation (0.3%), and extended criteria donors (6.3% in 2013) [22], and were therefore not considered in further analyses. Besides a recipient’s hypertension history which is often ill-defined, all recipient’s cardiovascular antecedents (hypertension, coronary heart disease, proximal or distal arteritis of lower limbs, transient ischemic cerebral episodes, or strokes) were collected as a risk factor for DGF. Besides donor’s weight, the more accurate BMI was computed. Moreover, recipient’s residual diuresis at the time of transplantation was also considered as a potential risk factor for DGF; indeed, if the function of native kidneys is not negligible but requires regular dialyses, one would expect the need of posttransplant dialysis to be lower.

Causes of donor’s death were distributed into two main groups: traumatic, resulting from traffic accident, fall, or gunshot, and nontraumatic, due to stroke, anoxia, or brain tumor.

Several demographic characteristics commonly considered as potentially influencing patient and graft survival were recorded: gender and age of the recipient and the donor,
number of the graft and pretransplant blood transfusions, duration of the pretransplant regular dialysis period, peak anti-HLA sensitization, cold and warm ischaemia times, DGF, number of HLA mismatches, oral immunosuppression, and induction therapy with poly- or monoclonal globulins.

All the data were collected from our own database or from that kindly provided by the Eurotransplant International Foundation which organizes all kidney exchanges within eight west-European countries including ours [22].

Statistical Methods. Fisher’s exact test or chi-square tests were used to compare groups with nominal variables and $F$ tests groups with numerical variables. Results were expressed as percent of the total for nominal variables and as mean and standard deviation for numerical variables.

A multivariate binary logistic regression model was used to identify the risk factors for rejection and DGF. A backward elimination procedure, based on likelihood ratio, was used to select variables to include in logistic regression models. The Hosmer-Lemeshow test was used to estimate the goodness of fit of our model. Continuous variables were categorized to test the linearity of the log odds scale computed from the logistic regression equation, and if nonlinear trends were identified for some variables, instead of introducing a quadratic term, a dichotomous category with special interest was created. Adjusted ORs and 95% CIs were derived from the final logistic models.

A receiver operating characteristic (ROC) curve was built from the results of the logistic regression in order to estimate the discriminant power of the factors which emerged from the logistic regression model. An area under the ROC curve and its 95% confidence interval were computed.

Univariate survival was computed according to the Kaplan-Meier method and the Cox proportional hazard method was used in multivariate survival analyses.

StatView [23] and Stata [2] statistical software packages were used in all analyses.

The study has been reviewed by the local ethics committee and has therefore been performed in accordance with the ethical standards of the Declaration of Helsinki 2000 as well as the Declaration of Istanbul 2008.

3. Results

3.1. Time Evolution of Risk Factors for DGF. The incidence of nearly all risk factors changed significantly in the course of time (Table 1). These changes occurred sometimes at random such as for regrafting and duration of the pretransplant dialysis period; some supervened abruptly such as for immunosuppression and perioperative saline loading, but most other changes were gradual, departing or not from linearity. Many risk factors were highly ($P < 0.001$) correlated: for instance, regrafting with peak HLA sensitization, immunosuppression and HLA mismatches with acute rejection episodes, and DGF with cold ischemia time. Grafts with missing data were predominantly encountered in the 1983–1997 period.

3.2. Incidence of DGF. Altogether, DGF was observed in 382 out of 1784 transplantations (21.4%) and its duration was limited to the first two posttransplant weeks in 81.4% of the cases (Table 2). Transplants in which acute rejection occurred during the DGF period had a significantly longer duration of DGF than those free of rejection ($P < 0.001$), the median difference between both groups being 5.5 days.

3.3. Causes of Donor’s Death. The cause of death was unknown in 100 transplant (5.6%). Five groups of known causes were considered: traumaism resulting from traffic accident, fall, or gunshot, cerebrovascular event (haemorrhagic or thrombotic), anoxia due to respiratory arrest induced by drugs or severe asthma, brain tumor, and other less frequent miscellaneous causes. By far, the first two causes were predominant (90.8%) and a clear relationship appeared between the cause of death and donor terminal creatinine, distinguishing traumatic from nontraumatic causes (Table 3): donor’s terminal creatinine was significantly higher in donors dead from trauma ($P < 0.001$) than in those dead from other causes ($P = 0.74$).

3.4. Risk Factor for Acute Rejection Occurring during the DGF Period. Rejection episodes that occurred before 1998 were distributed according to their impact on kidney function [21] and those from 1998 to 2014 according to three Banff grades: borderline, grades Ia and Ib (24%), grade IIa (66%), and grade IIb (10%). After including all risk factors listed in Table 1 in a multivariable logistic regression analysis, seven of them were significant, all the others being excluded from the model at $P > 0.10$ (Table 4). Thus, peak HLA sensitization, prolonged pretransplant dialysis period, absence of use of antilymphocyte induction therapy, mycophenolate mofetil and perioperative saline loading, high number of HLA mismatches, and young recipient’s age were detrimental for rejection.

3.5. Risk Factors for DGF. Continuous variables were categorized to test the linearity of the response to DGF. This response did not depart from linearity for warm and cold ischemia times, recipient’s and donor’s age, recipient’s and donor’s BMI, and DCD donors, at variance with recipient’s residual diuresis for which 500 mL/d was a significant cut-off value ($P < 0.001$) justifying the creation of a dichotomous variable: <500 (64.5% of grafts) versus $\geq$ 500 mL/d (35.5% of grafts). The final model included seven risk factors, all the others being excluded at $P > 0.10$: cold ischaemia time, recipient’s residual diuresis <500 mL/d, perioperative saline loading, recipient’s BMI, DCD donor, donor’s terminal creatinine, and recipient’s gender. These results were nearly identical whether rejection episodes occurring during the DGF period were taken into account (1155 grafts with complete data [65% of the total]: 976 without DGF and 179 with DGF, upper part of Table 5) or not (1069 grafts [68% of the total]: 911 without DGF and 158 with DGF, lower part of Table 5). Of note, cardiovascular antecedents were more frequent in male than in female recipients: 12.6 versus 8.6% ($P = 0.01$). Restricting the analysis to the 1998–2014 period in which transplants with incomplete data were less frequent (31% out of 978 grafts: Table 1) did not substantially
Table 1: Time evolution of demographic characteristics in 1784 transplantations performed from 1983 to 2014.

| Transplant years | 1983–1991 | 1992–1997 | 1998–2003 | 2004–2009 | 2010–2014 | P value | Number of missing values |
|------------------|-----------|-----------|-----------|-----------|-----------|---------|--------------------------|
| Number of grafts | 421       | 385       | 346       | 353       | 279       | <1998   | ≥1998                    |
| Male gender      | 60.8      | 61.8      | 61.9      | 62.9      | 62.0      | 0.99    |                          |
| Age (y)          | 35.8 ± 9.7| 39.1 ± 11.1| 46.7 ± 12.4| 50.6 ± 12.4| 53.1 ± 12.8| <0.001  |                          |
| Regrafting       | 20.2      | 17.1      | 26.3      | 13.6      | 15.1      | <0.001  |                          |
| Duration of regular dialysis (y) | 3.5 ± 3.0 | 3.7 ± 3.0 | 4.1 ± 4.6 | 3.1 ± 2.9 | 3.5 ± 3.1 | 0.007   |                          |
| History of diabetes | 1.1       | 0         | 4.0       | 11.9      | 15.1      | <0.001  |                          |
| History of cardiovascular disease | 4.8       | 6.5       | 10.4      | 22.4      | 13.6      | <0.001  |                          |
| Peak (>50% PRA) sensitization | 20.7      | 6.8       | 9.2       | 8.2       | 6.1       | <0.001  |                          |
| Delayed graft function (DGF) | 48.7      | 17.7      | 16.5      | 11.0      | 4.7       | <0.001  |                          |
| Perioperative saline loading | 0         | 100       | 100       | 100       | 100       | <0.001  |                          |
| Use of mycophenolate mofetil | 0         | 4.9       | 83.5      | 92.1      | 98.9      | <0.001  |                          |
| Immunoglobulin induction | 56.5      | 95.3      | 78.6      | 92.9      | 98.9      | <0.001  |                          |
| ARE occurring during DGF period | 27.3      | 10.7      | 5.8       | 6.3       | 3.6       | <0.001  |                          |
| Biopsy proven | 79.8      | 90.4      | 94.2      | 94.6      | 96.8      | <0.001  |                          |
| Residual diuresis (<500 mL/24h) | 69.0      | 66.5      | 64.5      | 51.3      | 52.3      | <0.001  | 267 127                  |
| BMI (kg/m²) | 22.7 ± 3.8| 23.9 ± 3.6| 24.5 ± 4.3| 25.2 ± 4.7| 25.3 ± 4.8| <0.001  | 271 126                  |
| Male gender      | 60.9      | 62.2      | 59.5      | 58.4      | 50.5      | 0.024   |                          |
| Age (y)          | 52.4 ± 14.3| 37.5 ± 14.4 | 42.7 ± 16.0| 44.0 ± 15.1| 48.8 ± 13.0| <0.001  |                          |
| Donation after cardiac death | 0         | 0         | 1.2       | 2.7       | 13.6      | <0.001  |                          |
| Traumatic cause of death | 57.9      | 45.7      | 40.8      | 34.9      | 27.2      | <0.001  | 11 8                     |
| Terminal serum creatinine (mg/dL) | 1.00 ± 0.39| 0.95 ± 0.36| 0.91 ± 0.33| 0.77 ± 0.31| 0.70 ± 0.25| <0.001  | 43 51                    |
| BMI (kg/m²) | 23.2 ± 4.0| 23.7 ± 3.5| 24.7 ± 4.2| 24.9 ± 4.6| 25.6 ± 4.3| <0.001  | 132 131                  |
| Ischaemia times |           |           |           |           |           |         |                          |
| Cold (h)         | 27.3 ± 7.6| 22.8 ± 6.2| 18.8 ± 6.0| 17.2 ± 5.0| 16.3 ± 5.5| <0.001  | 0 2                      |
| Warm (min)       | 34.2 ± 7.9| 33.0 ± 7.8| 33.2 ± 8.3| 30.0 ± 7.5| 32.6 ± 9.0| <0.001  | 0 2                      |
| Number of HLA-A+B+DR mismatches | 2.6 ± 1.5| 2.2 ± 1.3| 2.7 ± 1.3| 2.5 ± 1.2| 2.6 ± 1.1| <0.001  |                          |

Nominal variables are expressed as percent of total grafts and numerical variables as mean ± standard deviation.
PRA: panel reactive antibodies; ARE: acute rejection episode; BMI: body mass index.

change the significance nor the relative power of the risk factors except for perioperative saline loading, which was not included in this analysis as all recipients benefited from it during that period (results not shown).

ROC curves estimating the discriminant power of the factors which emerged from the logistic analysis were computed. The area under the curve was nearly identical whether rejection episodes were taken into account (0.774, 95% CI: 0.74–0.81, Figure 1(a)) or not (0.769, 95% CI: 0.73–0.81, Figure 1(b)).

3.6. Impact of DGF on Patient and Graft Outcome. Survival was studied in three groups according to presence (+) or absence (−) of DGF and ARE: group 1 DGF−/ARE− (n = 1402), group 2 DGF+/ARE− (n = 300), and group 3 DGF+/ARE+ (n = 82). Patient survival was similar in the three groups: at ten years it was 84.5% in group 1, 86.8% in group 2, and 86.5% in group 3 (P = 0.54). On the contrary, whereas no difference in deceased censored graft survival was observed between groups 1 and 2 (P = 0.45), survival was much lower (P < 0.001) in group 3 than in the other
Table 2: Delayed graft function (DGF) in transplants with and without acute rejection episodes (ARE) occurring during the DGF period.

| Posttransplant weeks | Total DGF | DGF without ARE | DGF with ARE |
|----------------------|-----------|-----------------|--------------|
|                      | n         | %    | n         | %          | n     | %          |
| 1st                  | 162       | 42.4 | 150       | 50.0       | 12    | 14.6       |
| 2nd                  | 149       | 39.0 | 114       | 38.0       | 35    | 42.7       |
| 3rd                  | 39        | 10.2 | 23        | 7.7        | 16    | 19.5       |
| 4th                  | 12        | 3.1  | 6         | 2.0        | 6     | 7.3        |
| >4th                 | 20        | 5.3  | 7         | 2.3        | 13    | 15.9       |
| Total DGF            | 382       | 100.0| 300       | 100.0      | 82    | 100.0      |
| Total transplants    | 1784      | 1576 | 208       |             |       |            |

Table 3: Relationship between donor’s cause of death and terminal serum creatinine.

| Cause of death               | n   | %   | Serum creatinine (mg/dL ± SEM) |
|------------------------------|-----|-----|-------------------------------|
| Number of missing data       | 100 | 5.6 |                               |
| Traumatic                    | 691 | 41.0| 0.95 ± 0.01                   |
| Cerebrovascular event        | 837 | 49.8| 0.82 ± 0.01                   |
| Anoxia                       | 115 | 6.8 | 0.79 ± 0.04                   |
| Brain tumor                  | 24  | 1.4 | 0.84 ± 0.06                   |
| Other                        | 17  | 1.0 | 0.85 ± 0.13                   |
| Nontraumatic                 | 993 | 59.0| 0.82 ± 0.01                   |
| All known causes             | 1684| 100.0|                               |

4. Discussion

Over the past three decades, DGF incidence has consistently fallen due to a better control of its predominant causal mechanisms, ischemia-reperfusion injury, and early occurring rejection episodes. Since the early nineties, these episodes decreased by the use of potent immunosuppressive regimens including mycophenolate mofetil [24] and monoclonal antibodies directed to T cell receptors [25] as well as a drastic reduction in recipient's HLA sensitization which was closely related to a drop in pretransplant blood transfusions. On the other hand, improved kidney allocation strategy within the US [6] and the Eurotransplant Organization at the end of the nineties [26] has considerably shortened cold ischemia time which constitutes a prominent risk factor for ischemia-reperfusion injury in spite of an increasing but limited rate in detrimental factors such as extended criteria and DCD donors, recipient's diabetes, high BMI, and cardiovascular antecedents [27].

In our centre, implementation of systematic perioperative saline loading since 1992 induced an immediate and impressive drop in DGF incidence that decreased more slowly thereafter, following a trend similar (but at lower values) to that reported in other centres. This observation prompted us to find an explanation for this discrepancy.

In order to distinguish the respective role of ischemia-reperfusion injury and acute rejection occurring during the DGF period, risk factors for rejection during the DGF period were studied. Along with well known factors (HLA sensitization, duration of regular pretransplant dialyses, use of mycophenolate mofetil and antilymphocyte globulin induction, HLA-A+B+DR match, and recipient’s age), perioperative saline loading significantly prevents acute rejection. As perioperative saline loading has been shown to decrease the risk of ischemia-reperfusion injury [28, 29] that enhances the susceptibility to rejection by activation of the innate immunity, which is deeply involved in alloimmunity [9], it is likely that perioperative saline loading reduces the immunologic mechanisms that elicit the rejection process.
Table 4: Multivariable logistic regression analysis of factors predicting acute rejection episodes occurring during the delayed graft function period in 1784 transplants performed from 1983 to 2014.

| Predictive factors                                      | Risk code          | Regression coefficient | P value | Odds ratio (95% CI) |
|---------------------------------------------------------|--------------------|------------------------|---------|--------------------|
| Constant                                                |                    | −2.119                 | <0.001  | 3.5 (2.4–5.2)      |
| Peak HLA sensitization (>50% PRA)                       | If yes, then 1, else 0 | 1.265                 | <0.001  | 3.5 (2.4–5.2)      |
| Duration of regular dialyses (years)                    | Increase per year   | 0.098                  | <0.001  | 1.003 (1.06–1.146) |
| Antilymphocyte globulin induction                       | If no, then 1, else 0 | 0.860                  | <0.001  | 2.4 (1.6–3.4)      |
| Recipient's age (years)                                 | Decrease per year   | −0.025                 | <0.001  | 0.975 (0.96–0.989) |
| HLA-A+B+DR mismatches (MM)                              | Increase per MM     | 0.206                  | <0.001  | 1.22 (1.09–1.39)   |
| Recipient's perioperative saline loading                | If no, then 1, else 0 | 0.624                  | 0.005   | 1.9 (1.2–2.9)      |
| Use of mycophenolate mofetil                            | If no, then 1, else 0 | 0.630                  | 0.007   | 1.9 (1.2–2.9)      |

Log likelihood chi-square (7 DF): 238.18, P < 0.0001. Goodness of fit: P = 0.85.

Table 5: Logistic regression analysis of factors predicting delayed graft function (DGF) with and without acute rejection episodes (ARE) occurring during the DGF period (grafts with complete data).

(a)

| Predictive factors                                      | Risk code          | Regression coefficient | P value | Odds ratio (95% CI) |
|---------------------------------------------------------|--------------------|------------------------|---------|--------------------|
| Grafts with ARE (n = 1155)                              |                    |                        |         |                    |
| Constant                                                |                    | −7.082                 | <0.001  | 1.094 (1.064–1.124) |
| Cold ischaemia time                                     | Increase per h      | 0.091                  | <0.001  | 2.3 (1.6–3.5)      |
| Recipient's residual diuresis                           | If <500 mL/d, then 1, else 0 | 0.851                 | <0.001  | 3.3 (2.0–5.4)      |
| Perioperative saline loading                            | If no, then 1, else 0 | 1.200                  | <0.001  | 3.6 (1.7–7.8)      |
| Donor after cardiac death                               | If yes, then 1, else 0 | 1.292                  | 0.004   | 1.068 (1.026–1.113) |
| Recipient's BMI                                         | Increase per kg/m²  | 0.066                  | 0.008   | 2.1 (1.3–3.4)      |
| Donor's terminal creatinine                             | Increase per mg/dL  | 0.730                  | 0.008   | 1.8 (1.2–2.7)      |
| Recipient's gender                                      | If male, then 1, else 0 | 0.594                  | 0.009   |                    |

Log likelihood chi-square (7 DF): 163.71, P < 0.0001. Goodness of fit: P = 0.80.

(b)

| Predictive factors                                      | Risk code          | Regression coefficient | P value | Odds ratio (95% CI) |
|---------------------------------------------------------|--------------------|------------------------|---------|--------------------|
| Grafts without ARE (n = 1069)                           |                    |                        |         |                    |
| Constant                                                |                    | −6.938                 | <0.001  | 1.096 (1.066–1.128) |
| Cold ischaemia time                                     | Increase per h      | 0.092                  | <0.001  | 3.3 (1.9–5.6)      |
| Perioperative saline loading                            | If no, then 1, else 0 | 1.182                  | <0.001  | 2.3 (1.6–3.5)      |
| Recipient's residual diuresis                           | If <500 mL/d, then 1, else 0 | 0.843                 | <0.001  | 2.0 (1.2–3.3)      |
| Recipient's BMI                                         | Increase per kg/m²  | 0.064                  | 0.003   | 1.056 (1.022–1.112) |
| Donor's terminal creatinine                             | Increase per mg/dL  | 0.681                  | 0.009   | 2.0 (1.2–3.3)      |
| Donation after cardiac death                            | If yes, then 1, else 0 | 1.079                  | 0.010   | 2.9 (1.3–6.7)      |
| Recipient's gender                                      | If male, then 1, else 0 | 0.351                  | 0.012   | 1.7 (1.1–2.5)      |

Log likelihood chi-square (7 DF): 137.34, P < 0.0001. Goodness of fit: P = 0.71.

Risk factors for DGF are very similar whether early occurring rejection episodes are taken into account or not. All these factors except perioperative saline loading are different from those for acute rejection. This suggests that ischemia-reperfusion injury is the predominant mechanism involved in the development of DGF. Several factors contribute to increase in ischemia-reperfusion injury and thereby DGF risk. Whether their effects are additive or enhance each other is difficult to establish. Anyhow, prolonged cold ischemia time, absence of perioperative saline loading, high recipient's BMI, male gender (which is highly correlated to his cardiovascular antecedents), DCD donors, and high donor's terminal creatinine (which is highly correlated to donor's traumatic death) are all detrimental for DGF, consistent with previously reported results [3]. A not yet described risk factor is recipient's residual diuresis. It reflects the function of the native kidneys and is likely to be associated with the nutritional, cardiovascular, and biochemical status of the recipient [30]. Therefore, it is not surprising that posttransplant dialysis is less indicated if recipient's diuresis is preserved.

When early occurring rejection episodes are taken into account, deceased censored graft survival is lower in grafts with DGF than in those without DGF, at variance with what is observed in rejection-free grafts. Long-term graft survival
depends mostly on immunologic processes inducing acute rejection [31] and, later on, chronic rejection [32], whereas ischemia-reperfusion injury is short-lived, limited to the first weeks after transplantation. The ambiguity concerning the role of DGF in graft survival is thus cleared away. Poor graft survival attributed to DGF in other studies might be due to unrecognized rejection [10–12, 33] and/or poorly characterized lower intrinsic kidney quality [34]. The differential effects of DGF on graft survival according to acute rejection episodes as well as the longer duration of DGF when it is associated with rejection further suggest that ischemia-reperfusion injury is the predominant factor responsible for DGF development and also that early occurring rejection episodes are to be considered in any study on DGF.

Area under the ROC curves derived from our logistic regression analyses, close to 0.77, shows an excellent discriminant power of the risk factors identified in our model and compares favourably with that reported (0.70) in a large multicentric study [3]. Moreover, restricting the analysis to the 236 grafts performed in our centre between 2003 and 2006, the DGF probability is 11% when using the twenty-two risk factors provided by the transplant calculator derived from the data of 2003–2006 [3] and 7.8% when using our model including seven risk factors. This further highlights the importance of the two novel risk factors which emerged from our study: recipient’s residual function of native kidneys and perioperative hemodynamics.

The usefulness of our model should be confirmed by internal validation in new patients using the same database as well as by external validation in patients from other databases using our model [35]. Indeed, our single centre retrospective study has some limitations: (a) the sample size is relatively small when compared with large multicentric studies, (b) DGF incidence is highly dependent on each centre as standardization of postoperative dialysis requirements is lacking, and (c) although our results were similar when restricting the analysis to the 1998–2014 period, it may be argued that recent changes in kidney transplant characteristics render obsolete data derived from a study starting in the eighties.

5. Conclusions

The current low DGF incidence in our centre, close to 5%, is, at least in part, related to systematic recipient’s perioperative saline loading that efficiently prevents ischemia-reperfusion injury, the predominant cause of DGF. Along with other factors, residual function of the native kidneys is another novel important factor emerging from our study. Our model affords excellent discriminant power to predict DGF. DGF significantly reduces graft survival only when early occurring rejection episodes are taken into account, suggesting that acute rejection should be considered in any study on DGF. As they are powerful determinants of rejection, recent immunosuppressive regimens and better donor-recipient HLA match might further contribute to reduction in DGF incidence.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

M. Chaumont collected data and wrote the paper in part; J. Racapé analyzed data; N. Broeders collected data and reviewed the paper; F. El Mountahi, A. Massart, T. Baudoux,
Acknowledgments

The authors are grateful to Mrs. N. Lietaer and A. Killens for their help in handling the database, to Mrs. E. Angenon for handling the waiting list of the patients, and to Mrs. F. Ouanda for her secretarial assistance.

References

[1] S. G. Yarlagadda, S. G. Coca, A. X. Garg et al., “Marked variation in the definition and diagnosis of delayed graft function: a systematic review,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2995–3003, 2008.
[2] A. Siedlecki, W. Irish, and D. C. Brennan, “Delayed graft function in the kidney transplant,” American Journal of Transplantation, vol. 11, no. 11, pp. 2279–2296, 2011.
[3] W. D. Irish, J. N. Ilsley, M. A. Schnitzler, S. Feng, and D. C. Brennan, “A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation,” American Journal of Transplantation, vol. 10, no. 10, pp. 2279–2286, 2010.
[4] S. K. Akkina, J. J. Connaire, A. K. Israni, J. J. Snyder, A. J. Matas, and B. L. Kasiske, “Similar outcomes with different rates of delayed graft function may reflect center practice, not center performance,” American Journal of Transplantation, vol. 9, no. 6, pp. 1460–1466, 2009.
[5] P. F. Halloran, “Immunosuppressive drugs for kidney transplantation,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2715–2729, 2004.
[6] A. S. Klein, E. E. Messersmith, L. E. Ratner, R. Kochik, P. K. Baliga, and A. O. Ojo, “Organ donation and utilization in the United States, 1999–2008: special feature,” American Journal of Transplantation, vol. 10, no. 4, pp. 973–986, 2010.
[7] A. Sharif and R. Borrows, “Delayed graft function after kidney transplantation: the clinical perspective,” American Journal of Kidney Diseases, vol. 62, no. 1, pp. 150–158, 2013.
[8] W. D. Irish, D. A. McCollum, R. J. Tesi et al., “Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2967–2974, 2003.
[9] C. Ponticelli, “Ischaemia-reperfusion injury: a major protagonist in kidney transplantation,” Nephrology Dialysis Transplantation, vol. 29, no. 6, pp. 1134–1140, 2014.
[10] H. I. Feldman, R. Gayner, J. A. Berlin et al., “Delayed function reduces renal allograft survival independent of acute rejection,” Nephrology Dialysis Transplantation, vol. 11, no. 7, pp. 1306–1313, 1996.
[11] D. A. Shoskes and J. M. Cecka, “Delterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection,” Transplantation, vol. 66, no. 12, pp. 1697–1701, 1998.
[12] F. Moreso, D. Serón, S. Gil-Vernet et al., “Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients,” Nephrology Dialysis Transplantation, vol. 14, no. 4, pp. 930–935, 1999.
[13] C. Troppmann, K. J. Gillingham, E. Benedetti et al., “Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: a multivariate analysis,” Transplantation, vol. 59, no. 7, pp. 962–968, 1995.
[14] D. Mikhailski, K. M. Wissing, L. Ghisdal et al., “Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression,” Transplantation, vol. 85, no. 7S, pp. S3–S9, 2008.
[15] S. G. Yarlagadda, S. G. Coca, R. N. Formica, E. D. Poggio, and C. R. Parikh, “Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 1039–1047, 2009.
[16] A. Sharif, S. Shabir, S. Chand, P. Cockwell, S. Ball, and R. Borrows, “Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation,” Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2107–2118, 2011.
[17] M. G. J. Snoeijis, B. Wiemans, M. H. Christiaans et al., “Recipient hemodynamics during non-heart-beating donor kidney transplantation are major predictors of primary nonfunction,” American Journal of Transplantation, vol. 7, no. 5, pp. 1158–1166, 2007.
[18] M. Chapal, F. Le Borgne, C. Legendre et al., “A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors,” Kidney International, vol. 86, pp. 1130–1139, 2014.
[19] C. Jeldres, H. Cardinal, A. Duclos et al., “Prediction of delayed graft function after renal transplantation,” Journal of the Canadian Urological Association, vol. 3, no. 5, pp. 377–382, 2009.
[20] P. Vereerstraeten, “Préparation du receveur de greffe rénale,” in Transplantation d’organes et greffe de tissus, P. Hervé, Ed., pp. 690–701, Editions Inserm, Paris, France, 1994.
[21] P. Vereerstraeten, D. Abramowicz, L. De Pauw, and P. Kinnaert, “Absence of deleterious effect on long-term kidney survival of rejection episodes with complete functional recovery,” Transplantation, vol. 63, pp. 1739–1743, 1997.
[22] A. Rahmel, Ed., Annual Report 2013, Eurotransplant International Foundation, Leiden, The Netherlands, 2013.
[23] Abacus Concepts, Survival Tools for Stat-View, Abacus Concepts, Berkeley, Calif, USA, 1994.
[24] S. R. Knight, N. K. Russell, L. Barcena, and P. J. Morris, “Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review,” Transplantation, vol. 87, no. 6, pp. 785–794, 2009.
[25] “KDIGO clinical practice guideline for the care of kidney transplant recipients. Chapter 1: induction therapy,” American Journal of Transplantation, vol. 9, supplement 3, pp. S6–S9, 2009.
[26] T. Wujciak and G. Opeil, “A proposal for improved cadaver kidney allocation,” Transplantation, vol. 56, no. 6, pp. 1513–1517, 1993.
[27] U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2013.
[28] M. Carlier, J. P. Squifflet, Y. Pirson, L. Decocq, B. Gribomont, and G. P. Alexandre, “Confirmation of the crucial role of the recipient’s maximal hydration on early diuresis of the human cadaver renal allograft,” Transplantation, vol. 36, no. 4, pp. 455–456, 1983.
[29] P. Schnuelle and F. J. van der Woude, “Perioperative fluid management in renal transplantation: a narrative review of the literature,” *Transplant International*, vol. 19, no. 12, pp. 947–959, 2006.

[30] A. Y.-M. Wang and K.-N. Lai, “The importance of residual renal function in dialysis patients,” *Kidney International*, vol. 69, no. 10, pp. 1726–1732, 2006.

[31] A. Ishikawa, S. M. Flechner, D. A. Goldfarb et al., “Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome,” *Transplantation*, vol. 68, no. 9, pp. 1318–1324, 1999.

[32] A. Humar, A. Hassoun, R. Kandaswamy, W. D. Payne, D. E. R. Sutherland, and A. J. Matas, “Immunologic factors: the major risk for decreased long-term renal allograft survival,” *Transplantation*, vol. 68, no. 12, pp. 1842–1846, 1999.

[33] F. Qureshi, H. Rabb, and B. L. Kasiske, “Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival,” *Transplantation*, vol. 74, no. 10, pp. 1400–1404, 2002.

[34] N. M. Butala, P. P. Reese, M. D. Doshi, and C. R. Parikh, “Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis,” *Transplantation*, vol. 95, no. 8, pp. 1008–1014, 2013.

[35] G. Tripepi, G. Heinze, K. J. Jager, V. S. Stel, F. W. Dekker, and C. Zoccali, “Risk prediction models,” *Nephrology Dialysis Transplantation*, vol. 28, no. 8, pp. 1975–1980, 2013.